




PHARMACEUTICAL 2021

Strongbridge Biopharma plc
Rank 229 of 402





RealRate

PHARMACEUTICAL 2021

Strongbridge Biopharma plc Rank 229 of 402

The relative strengths and weaknesses of Strongbridge Biopharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Strongbridge Biopharma plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Strongbridge Biopharma plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 77%, being 29% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	92,352
Cost of Goods Sold	0
Intangible Assets	27,344
Liabilities, Current	21,131
Liabilities, Non-Current	17,867
Other Assets	1,188
Other Compr. Net Income	-3.0
Other Expenses	7,219
Other Liabilities	16,497
Other Net Income	-1,925
Other Revenues	30,731
Property and Equipment	216
Research and Development	25,795
Selling, General and Administrative Expense	40,867

Output Variable	Value in 1000 USD
Assets	121,100
Liabilities	55,495
Expenses	73,881
Revenues	30,731
Stockholders Equity	65,605
Net Income	-45,075
Comprehensive Net Income	-45,076
Economic Capital Ratio	77%